**1) Sponsor(s):**Department of Education

**Program Title:** Promise Neighborhoods (PN) Programs

**Deadline:** February 3, 2021 (Notice of Intent to Apply)

**Description of Opportunity:** The PN program is authorized under the Elementary and Secondary Education Act of 1965, as amended (ESEA). The purpose of the PN program is to significantly improve the academic and developmental outcomes of children living in the most distressed communities of the United States, including ensuring school readiness, high school graduation, and access to a community-based continuum of high-quality services. The program serves neighborhoods with high concentrations of low-income individuals; multiple signs of distress, which may include high rates of poverty, childhood obesity, academic failure, and juvenile delinquency, adjudication, or incarceration; and schools implementing comprehensive support and improvement activities or targeted support and improvement activities under section 1111(d) of the ESEA. All strategies in the continuum of solutions must be accessible to children with disabilities and English learners.

**2) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2](https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html)

**Deadline:** February 5, 2021

**Description of Opportunity:** Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus, SARS-CoV-2, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, Hubei Province, China. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (https://www.cdc.gov/coronavirus/index.html) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of viral pathogenesis, natural history, and host range are poorly understood. Given this, there is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions.

NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

* Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
* Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
* Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

**3) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) – Research on Rehabilitation Needs Associated with the COVID-19 Pandemic](https://grants.nih.gov/grants/guide/notice-files/NOT-HD-20-031.html)

**Deadline:** February 5, 2021

**Description of Opportunity:** The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:

1. Encourage research to address the rehabilitation needs of survivors of COVID-19

2. Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions

3. Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities

Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the National Center for Medical Rehabilitation Research (NCMRR) at NICHD.

**4) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-030.html)

**Deadline:** February 6, 2021

**Description of Opportunity:** NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.

**5) Sponsor(s):**Department of Health and Human Services

**Program Title:** [Community Health Access and Rural Transformation (CHART)](https://www.grants.gov/web/grants/view-opportunity.html?oppId=329062)

**Deadline:** February 16, 2021

**Description of Opportunity:** The Community Health Access and Rural Transformation (CHART) Model is a voluntary payment model designed to meet the unique needs of rural communities. The CHART Model will test whether aligned financial incentives, increased operational flexibility, and robust technical support promote rural health care providers’ capacity to implement effective health care delivery system redesign on a broad scale. The Center for Medicare & Medicaid Innovation (CMMI) will evaluate the impact of the CHART Model on Medicare and Medicaid expenditures, access to care, quality of care, and health outcomes for rural residents.

CHART aligns with CMS’s Rethinking Rural Health initiative, which aims to ensure individuals in rural America have access to high quality, affordable health care by offering new and creative payment models. The CHART Model will include two tracks: 1) the Community Transformation Track and 2) the Accountable Care Organization (ACO) Transformation Track. This Notice of Funding Opportunity (NOFO) is for the Community Transformation Track only. Under the Community Transformation Track, award recipients will receive cooperative agreement funding and a programmatic framework to assess the needs of their Community (as defined in section A.4.3.1. Community Definition below) and implement health care delivery system redesign. Hospitals participating in the Community Transformation Track Alternative Payment Model (APM) will receive capitated payments. Capitated payments provide hospitals with a stable revenue stream and incentivize reductions in fixed costs and avoidable utilization. Operational flexibilities will be available for participating hospitals to relieve regulatory burden, emphasize high-value services, and support providers in care management for their beneficiaries.

**6) Sponsor(s):**Department of Health and Human Services

**Program Title:** [Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services to Mitigate Morbidity and Mortality](https://www.grants.gov/web/grants/view-opportunity.html?oppId=329756)

**Deadline:** February 18, 2021

**Description of Opportunity:** The purpose of this notice of funding opportunity is to understand the needs of emergency-affected and displaced populations by improving epidemiological methods, estimating morbidity and mortality of these populations during COVID-19, as well as understand the specific health sector needs of persons affected by humanitarian /public health emergencies and best practices for improving health outcomes.

**7) Sponsor(s):**National Science Foundation (NSF)

**Program Title:** [Smart and Connected Communities](https://www.grants.gov/web/grants/view-opportunity.html?oppId=330047)

**Deadline:** February 24, 2021

**Description of Opportunity:** Communities in the United States (US) and around the world are entering a new era of transformation in which residents and their surrounding environments are increasingly connected through rapidly-changing intelligent technologies. This transformation offers great promise for improved wellbeing and prosperity but poses significant challenges at the complex intersection of technology and society. The goal of the NSF Smart and Connected Communities (S&CC) program solicitation is to accelerate the creation of the scientific and engineering foundations that will enable smart and connected communities to bring about new levels of economic opportunity and growth, safety and security, health and wellness, accessibility and inclusivity, and overall quality of life.

For the purposes of this solicitation, communities are defined as having geographically-delineated boundaries—such as towns, cities, counties, neighborhoods, community districts, rural areas, and tribal regions—consisting of various populations, with the structure and ability to engage in meaningful ways with proposed research activities. A “smart and connected community” is, in turn, defined as a community that synergistically integrates intelligent technologies with the natural and built environments, including infrastructure, to improve the social, economic, and environmental well-being of those who live, work, learn, or travel within it.

The S&CC program encourages researchers to work with community stakeholders to identify and define challenges they are facing, enabling those challenges to motivate use-inspired research questions. For this solicitation, community stakeholders may include some or all of the following: residents, neighborhood or community groups, nonprofit or philanthropic organizations, businesses, as well as municipal organizations such as libraries, museums, educational institutions, public works departments, and health and social services agencies. The S&CC program supports integrative research that addresses fundamental technological and social science dimensions of smart and connected communities and pilots solutions together with communities. Importantly, the program is interested in projects that consider the sustainability of the research outcomes beyond the life of the project, including the scalability and transferability of the proposed solutions.

This S&CC solicitation will support research projects in the following categories:

* S&CC Integrative Research Grants (SCC-IRG) Tracks 1 and 2. Awards in this category will support fundamental integrative research that addresses technological and social science dimensions of smart and connected communities and pilots solutions together with communities. Track 1 proposals may request budgetsranging between $1,500,001 and $2,500,000, with durations of up to four years. Track 2 proposals may request budgetsup to $1,500,000, with durations of up to three years. Note that NSF is working with the Japan Science and Technology Agency (JST) to support joint US-Japan IRG Track 2 proposals (SCC-IRG JST) that address topics related to recovery from COVID-19 and future resilience planning related to pandemics and disasters, including how the proposed research will enable community adjustment to life in the new normal of a post-COVID-19 society.
* S&CC Planning Grants (SCC-PG). Awards in this category are for capacity building to prepare project teams to propose future well-developed SCC-IRG proposals. Each of these awards will provide support for a period of one year and may be requested at a level not to exceed $150,000 for the total budget.
* S&CC Virtual Organization (SCC-VO). Proposals are being sought to establish a Virtual Organization that will: (i) facilitate and foster interaction and exchanges among S&CC PIs and their teams, including community partners; (ii) enable sharing of artifacts and knowledge generated by S&CC projects with the broader scientific and non-academic communities (e.g., local community stakeholders as described in this solicitation); and (iii) facilitate and foster collaboration and information exchange between S&CC researchers, community stakeholders, and others. No more than one S&CC-VO proposal will be funded. Funding of up to $250,000 per year for up to three years may be requested.

S&CC is a cross-directorate program supported by NSF’s Directorates for Computer and Information Science and Engineering (CISE), Education and Human Resources (EHR), Engineering (ENG), and Social, Behavioral, and Economic Sciences (SBE).

**8) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-243.html)

**Deadline:** Applications due on August 20, 2020, December 2, 2020, and March 2, 2021

**Description of Opportunity:** This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

**9) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Physiologically Based Pharmacokinetic (PBPK) Models of Oral Absorption to Simulate the Results of Bioequivalence Studies (U01) Clinical Trials Optional](https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-012.html)

**Deadline:** March 15, 2021

**Description of Opportunity:** Physiologically based pharmacokinetic (PBPK) models are an effective tool to integrate information about the product characteristics, the physiology of the individual subject, and the variability among subjects within a population to simulate the absorption and subsequent systemic disposition of the drug without conducting in vivo pharmacokinetic studies. These PBPK models have shown promise in supporting generic drug development and regulatory decision making. This opportunity solicits research proposals to expand the application of oral PBPK models to emerging issues in generic drug fields by providing the ability to simulate bioequivalence studies under various conditions.

**10) Sponsor(s):** Employment and Training Administration

**Program Title:** [Pathway Home 2](https://www.grants.gov/web/grants/view-opportunity.html?oppId=330958)

**Deadline:** March 16, 2021

**Description of Opportunity:** The purpose of this pilot program is to provide eligible, incarcerated individuals in state correctional facilities or local or county jails with workforce services prior to release and to continue services after release by transitioning the participants into reentry programs in the communities to which they will return. These grants are job-driven and build connections to local employers that will enable transitioning offenders to secure employment.

These projects ensure that transitioning offenders are prepared to meet the needs of their local labor markets with the skills valued by employers. Applicants must ensure that occupational training provided has no federal, state, or local regulations that restrict individuals with criminal records from obtaining licenses or other necessary credentials in that career. Therefore, applicants will need to research existing barriers for individuals with criminal records in relation to specific industries. Employer connections will inform specific program curricula and ensure relevance to the needs of local businesses and jobs. Teaching transitioning offenders foundational skills, such as job readiness, employability, and job search strategies, in addition to providing apprenticeships and occupational training leading to industry-recognized credentials, can provide access to employment and reduce the likelihood of reoffending.

**11) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-21-006.html)

**Deadline:** March 17, 2021

**Description of Opportunity:** National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include the following:

* Testing a publicly posted therapeutic candidate for use to treat COVID-19. Examples include clinical candidate therapeutics in documents publicly posted by the World Health Organization (types/classes of candidate therapeutics) and (candidates for clinical evaluation).
* Testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach.
* Testing of existing therapeutic candidates that work on mechanistic targets shared among other viruses that may be relevant to SARS-CoV-2.

PAR-17-465 Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)

PAR-18-462 Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34 Clinical Trial Not Allowed)

PAR-18-332 Clinic Testing Therapeutic/Indication Pairing Strategies (U01 Clinical Trial Required)

**12) Sponsor(s):**National Science Foundation (NSF)

**Program Title:** [Future of Work at the Human-Technology Frontier: Core Research (FW-HTF)](https://www.nsf.gov/pubs/2021/nsf21548/nsf21548.htm)

**Deadline:** March 23, 2021

**Description of Opportunity:** The overarching vision of this program is to support multi-disciplinary research to sustain economic competitiveness, to promote worker well-being, lifelong and pervasive learning, and quality of life, and to illuminate the emerging social and economic context and drivers of innovations that are shaping the future of jobs and work.

For the purposes of this solicitation, work is defined as mental or physical activity to achieve tangible benefit such as income, profit, or community welfare. A proposal for a research grant in this program must focus on advancing fundamental understanding of future work and work outcomes for workers and society.

The specific objectives of the Future of Work at the Human-Technology Frontier program are to (1) facilitate multi-disciplinary or convergent research that employs the joint perspectives, methods, and knowledge of behavioral science, computer science, design, economics, engineering, learning sciences, research on adult learning and workforce training, and the social sciences; (2) support deeper understanding of the societal infrastructure that accompanies and leads to new work technologies and new approaches to work and jobs, and that prepares people for the future world of work; (3) encourage the development of a research community dedicated to designing intelligent technologies and work organization and modes inspired by their positive impact on individual workers, the work at hand, the way people learn and adapt to technological change, creative and inclusive workplaces (including remote locations, homes, classrooms, or virtual spaces), and benefits for social, economic, educational, and environmental systems at different scales; (4) promote deeper basic understanding of the interdependent human-technology partnership to advance societal needs by advancing design of intelligent work technologies that operate in harmony with human workers, including consideration of how adults learn the new skills needed to interact with these technologies in the workplace, and by enabling broad and diverse workforce participation, including improving accessibility for those challenged by physical or cognitive impairment; and (5) understand, anticipate, and explore ways of mitigating potential risks including inequity arising from future work at the human-technology frontier.

Proposals to this program should describe multi-disciplinary or convergent research that addresses technological, human, and societal dimensions of future work. Technological innovations should be integrated with advances in behavioral science, computer science, economic science, engineering, learning sciences, research on adult learning and workforce training, and the social sciences. Proposals that address the impact of large-scale disruptions such as the Covid-19 pandemic on the future of jobs and work are also of interest.

**13) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [INTUIT-PC: Improving Nonsurgical Treatment of Urinary Incontinence among women in Primary Care: Dissemination and Implementation of PCOR Evidence (U18)](https://grants.nih.gov/grants/guide/rfa-files/RFA-HS-21-001.html)

**Deadline:** March 24, 2021

**Description of Opportunity:** The Agency for Healthcare Research and Quality (AHRQ) seeks applications to disseminate and implement in primary care practices the latest patient-centered outcomes research (PCOR) evidence regarding nonsurgical treatments for urinary incontinence in women.

This initiative will fund up to 5 projects to use lessons learned from previous AHRQ primary care practice improvement initiatives to implement and test implementation strategies to address urinary incontinence in women, and to integrate it with specialty care. Projects may draw on community-based resources and/or include multilevel implementation strategies aligning improvement strategies between primary care practices and healthcare systems.

**14) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html)

**Deadline:** March 25, 2021

**Description of Opportunity:** This supports research on coronavirus disease with a particular focus on viral natural history, pathogenicity and transmission. The maximum project duration is two years.

**15) Sponsor(s):**Department of Education

**Program Title:** [Equity Assistance Centers Assistance](https://www.grants.gov/web/grants/view-opportunity.html?oppId=330836)

**Deadline:** March 29, 2021

**Description of Opportunity:** The Equity Assistance Centers (EAC) program is authorized under title IV of the Civil Rights Act of 1964, 42 U.S.C. 2000c—2000c–2, 2000c–5, and the implementing regulations in 34 CFR part 270. This program awards grants through cooperative agreements to operate regional EACs that provide technical assistance (including training) at the request of school boards and other responsible governmental agencies in the preparation, adoption, and implementation of plans for the desegregation of public schools--which in this context means plans for equity (including desegregation based on race, national origin, sex, and religion)--and in the development of effective methods of coping with special educational problems occasioned by desegregation. Desegregation assistance, per 34 CFR 270.4, may include, among other activities: (1) dissemination of information regarding effective methods of coping with special educational problems occasioned by desegregation; (2) assistance and advice in coping with these problems; and (3) training designed to improve the ability of teachers, supervisors, counselors, parents, community members, community organizations, and other elementary or secondary school personnel to deal effectively with special educational problems occasioned by desegregation. A project must provide technical assistance in all four of the desegregation assistance areas: race, sex, national origin, and religion desegregation. Additionally, EACs provide critical support to help ensure that all students have access to positive and safe learning environments that meet their needs and are free of bullying, violence, and disruptive actions.

**16) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

**17) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

**18) Sponsor(s):**National Science Foundation

**Program Title:** [Dear Colleague Letter: Future of International Research Collaboration Post COVID-19](https://www.nsf.gov/pubs/2020/nsf20132/nsf20132.jsp)

**Deadline:** March 31, 2021

**Description of Opportunity:** This letter invites Rapid Response Research (RAPID) and EArly-concept Grants for Exploratory Research (EAGER) proposals for research to clarify lessons from the COVID-19 pandemic for international collaboration and research to strengthen international collaboration in the future. Proposals must focus on research topics unique to international engagement. Proposals should be submitted by institutions eligible to submit proposals to NSF and must include international collaboration as an integral part of the work. NSF encourages proposals from diverse teams. Proposals from early career investigators are especially welcome.

Research topics of interest include, but are not limited to:

1. Type I: Research to Clarify Lessons from the COVID-19 Pandemic for International Collaboration
	* Analyzing and synthesizing data from U.S. and international sources on the nature and scope of COVID-19 impacts to illuminate trends in international collaboration;
	* Evaluating the effectiveness of interventions to adapt to the COVID-19 pandemic environment;
	* Addressing the unique challenges of field work and other site-specific research.
2. Type II: Research to Strengthen International Collaboration for the Future
	* Reimagining international collaboration to enhance research productivity and accelerate progress in science and engineering;
	* Improving preparedness to make international collaboration more resilient, moving beyond traditional approaches centered on travel and remote access;
	* Leveraging lessons of COVID-19 experience in the U.S. and abroad to broaden participation in international collaborations.

**19) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-020.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for linked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. This FOA runs in parallel with companion FOAs that seek applications for single, unlinked Research Project Sites ([RFA-DA-21-021](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-021.html)), a single Consortium Administrative Core ([RFA-DA-21-022](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-022.html)) and a single Data Coordinating Center ([RFA-DA-21-023](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-023.html)). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. This FOA seeks applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.

**20) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [HEAL Initiative: HEALthy Brain and Child Development Study (U01 - Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-021.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for unlinked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative agreement award mechanism. This FOA runs in parallel with companion FOAs that seek applications for linked Research Project Sites ([RFA-DA-21-020](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-020.html)), a single Consortium Administrative Core ([RFA-DA-21-022](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-022.html)) and a single Data Coordinating Center ([RFA-DA-21-023](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-023.html)). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. This FOA seeks applications to create a consortium of research sites in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.

**21) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [HEAL Initiative: HEALthy Brain and Child Development Consortium Administrative Core (U24 - Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-022.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. This FOA runs in parallel with companion FOAs that seek applications for linked ([RFA-DA-21-020](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-020.html)) and unlinked ([RFA-DA-21-021](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-021.html)) research sites and a single Data Coordinating Center ([RFA-DA-21-023](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-023.html)). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. The HBCD Consortium Administrative Core (HCAC) will be responsible for providing the organizational framework for the management, direction, and overall coordination of the national multi-site consortium. It will coordinate the interactions of the individual Research Project Sites and the HBCD Data Coordinating Center. The Consortium Administrative Core will include Administrative and Project Management Plans, and will also be responsible for managing collaborative activities such as the functions of an Expert Scientific Board and oversight of an internal Steering Committee. See Section I (Funding Opportunity Description) below for more information.

**22) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [HEAL Initiative: HEALthy Brain and Child Development Data Coordinating Center (U24)](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-023.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for a Data Coordinating Center for the HEALthy Brain and Child Development Study. This FOA runs in parallel with companion FOAs that solicit applications for linked ([RFA-DA-21-020](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-020.html)) and unlinked ([RFA-DA-21-021](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-021.html)) research sites and a single Consortium Administrative Core ([RFA-DA-21-022](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-022.html)). It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, and participate in project data collection and harmonization activities of HBCD research sites. The HBCD Data Coordinating Center (HDCC) will develop (and revise as necessary) the procedures for collection of the core neuroimaging, neuropsychological, and other phenotypic assessment data in a manner that will maximize comparability across the individual research sites of the consortium for the HBCD longitudinal study. The center will perform quality control, data curation, and analysis for the measures collected from the research sites as well as provide data informatics tools for sites and NIH program staff to monitor consortium progress and performance and explore the curated data. The HDCC will facilitate cross-site pooling of data, create a database across assessment modalities, and harmonize with existing large-scale neurodevelopmental research efforts. The successful applicant will propose a secure bioinformatics platform for data storage, harmonization and sharing that enables effective communication of detailed research data, tools for data access and analysis, supporting documentation and necessary training materials. The HDCC should include a director (or co-directors) and one or more associate directors to ensure that the wide scope of activities -- functions of supporting the HBCD Study consortium data and informatics enterprise and acting as a resource center to the scientific community at large -- are seamlessly coordinated.

**23) Sponsor(s):**Health Resources and Services Administration

**Program Title:** [Evidence Based Telehealth Network Program](https://www.grants.gov/web/grants/view-opportunity.html?oppId=329771)

**Deadline:** April 2, 2021

**Description of Opportunity:** This notice announces the opportunity to apply for funding under the Evidence Based Telehealth Network Program (EB THNP). The two-fold purpose of this award is (1) to demonstrate how health networks can increase access to health care services utilizing telehealth technologies and (2) to conduct evaluations of those efforts to establish an evidence base for assessing the effectiveness of telehealth care for patients, providers, and payers.

**24) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html)

**Deadline:** April 5, 2021

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

**25) Sponsor(s):**LifeArc

**Program Title:** [Coronavirus therapeutics – call for rapid deployment](https://www.lifearc.org/funding/covid-19/covid-19-funding)

**Deadline:** April 6, 2021

**Description of Opportunity:** LifeArc invites applications for its coronavirus therapeutics call. This supports the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. The primary purpose is to accelerate availability of treatments for patients and it is therefore expected that applicants will already have material available for testing and a plan for rapid scale up of clinical material. Priority will be given to projects that have a clear path and availability for patients in a 6-12 month timeframe.

**26) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System](https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-051.html)

**Deadline:** April 14, 2021

**Description of Opportunity:** NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Research Objectives:

In order to rapidly improve our understanding of the neurological consequences of infection of SARS-CoV-2 and of COVID-19, NINDS is encouraging the submission of applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus that are directly related to the NINDS mission.

**27) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html)

**Deadline:** April 15, 2021

**Description of Opportunity:** NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

**28) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA](https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-011.html)

**Deadline:** April 15, 2021

**Description of Opportunity:** The impact of the COVID-19 pandemic on the nation is vast, especially on health and well-being. Research suggests that alcohol consumption tends to increase during times of duress and uncertainty such as disasters and other traumatic events, and as such alcohol is often misused to cope with stress, anxiety, and other uncomfortable emotions. In addition, the misuse of alcohol to cope with the stress as a result of physical distancing and other policy measures, and a lack of access to supportive social networks and treatment for people with pre-existing alcohol use disorder (AUD) are significant concerns during the pandemic. These outcomes are particularly challenging with respect to COVID-19 because alcohol misuse can interfere with normal immune system function and elevate susceptibility to viral infections of the respiratory system. Alcohol-associated damage to the liver, heart, and other organs may also complicate health outcomes in individuals with COVID-19. These myriad physical and behavioral health outcomes related to alcohol and COVID-19 present a range of urgent research needs and opportunities.

Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation’s response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. Such studies also will help to lay the groundwork for responding to future public health emergencies. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.

**29) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA](https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-011.html)

**Deadline:** April 15, 2021

**Description of Opportunity:** The impact of the COVID-19 pandemic on the nation is vast, especially on health and well-being. Research suggests that alcohol consumption tends to increase during times of duress and uncertainty such as disasters and other traumatic events, and as such alcohol is often misused to cope with stress, anxiety, and other uncomfortable emotions. In addition, the misuse of alcohol to cope with the stress as a result of physical distancing and other policy measures, and a lack of access to supportive social networks and treatment for people with pre-existing alcohol use disorder (AUD) are significant concerns during the pandemic. These outcomes are particularly challenging with respect to COVID-19 because alcohol misuse can interfere with normal immune system function and elevate susceptibility to viral infections of the respiratory system. Alcohol-associated damage to the liver, heart, and other organs may also complicate health outcomes in individuals with COVID-19. These myriad physical and behavioral health outcomes related to alcohol and COVID-19 present a range of urgent research needs and opportunities.

Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation’s response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. Such studies also will help to lay the groundwork for responding to future public health emergencies. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.

Questions that may be addressed under this NOSI include, but are not limited to:

* Are individuals who engage in high-risk drinking behaviors or with AUD more likely to engage in behaviors that increase risks for infection or transmission of SARS-CoV-2, the virus that causes COVID-19?
* What is the influence of alcohol drinking history, patterns, amount, and duration on susceptibility to SARS-CoV-2 infection and COVID-19 prevalence, progression, and outcomes? Are people living with HIV differentially affected? Are racial, ethnic and gender minorities and those of low socioeconomic background, or pregnant women or individuals with underlying conditions differentially affected?
* What are the common mechanisms of alcohol-associated Acute Respiratory Distress Syndrome (ARDS) and COVID-19-related ARDS? Are there mechanistic synergies or distinctions that can be exploited to manage COVID-19 progression?
* What are the broad physiological and pathological mechanisms mediating the impact of alcohol use and misuse on SARS-CoV2 infection and COVID-19 progression and complications? In immune compromised persons, or persons with other underlying co-morbid conditions, what additional physiological factors mediate the impact of alcohol misuse on SARS-CoVo2 infection and COVID-19 progression and outcomes?
* Does alcohol misuse mediate multi-organ or multi-system disruption, including neuroinflammation, to alter the severity and progression of COVID-19?
* Does COVID-19-related systemic inflammation accompanied by concomitant alcohol use exacerbate the neuroinflammation associated with AUD?
* Is SARS-CoV-2 neuroinvasive, similar to some other coronaviruses? How does alcohol impact the susceptibility and consequences of neurobiological manifestations of coronaviruses?
* Do the COVID-19 pandemic and the personal, social, policy, and economic responses and consequences impact stress and emotional regulation, thereby exacerbating the social isolation that increases the risk of alcohol misuse, potentially leading to harmful consequences of high-risk drinking behavior to self and others? What is the impact of social distancing on AUD treatment, recovery, relapse risk, and management of withdrawal? How do demographic, socio-cultural, and/or geographic differences affect recovery for individuals with AUD?
* How does the system-level shift towards COVID-19 impact access to primary and specialty health care for AUD and co-occurring mental health conditions? What are the systems-level challenges (policy, practice, financing) to rapid deployment of emergency mental health/AUD services during the pandemic?
* What workforce development and deployment strategies are needed to address emerging challenges in mental health/AUD treatment during the pandemic?

**30) Sponsor(s):**Department of Agriculture – National Institute of Food and Agriculture (NIFA)

**Program Title:** [Rural Health and Safety Education Competitive Grants Program (RHSE)](https://www.grants.gov/web/grants/view-opportunity.html?oppId=329476)

**Deadline:** April 29, 2021

**Description of Opportunity:** The RHSE program proposals are expected to be community-based outreach education programs, such as those conducted through Human Science extension outreach that provide individuals and families with: information as to the value of good health at any age; information to increase individual or family’s motivation to take more responsibility for their own health; information regarding rural environmental health issues that directly impact human health; information about and access to health promotion and educational activities; and training for volunteers and health services providers concerning health promotion and health care services for individuals and families in cooperation with state, local, and community partners.

Eligibility: Applications may be submitted by 1862 and 1890 Land Grant colleges and universities that are eligible to receive funds under the Act of July 2, 1862 (7 U.S.C. 301 et seq.), and the Act of

August 30, 1890 (7 U.S.C. 321 et seq.), including Central State University, Tuskegee University,

West Virginia State University. Applications also may be submitted by any of the Tribal colleges

and universities designated as 1994 Land Grant Institutions under the Educational Land-Grant

Status Act of 1994, as amended.

**31) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html)

**Deadline:** May 1, 2021

**Description of Opportunity:** NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements ([PA-18-591](https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html)) or Competitive Revisions ([PA-18-935](https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html)) to active grants.

**32) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities](https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html)

**Deadline:** May 1, 2021

**Description of Opportunity:** The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

**33) Sponsor(s):**Centers for Disease Control and Prevention

**Program Title:** [Coronavirus Response Fellowship](https://www.zintellect.com/Opportunity/Details/CDC-CSTLTS-2020-0086)

**Deadline:** May 1, 2021

**Description of Opportunity:** A research opportunity is currently available with the Center for State, Tribal, Local, and Territorial Support (CSTLTS) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. CSTLTS seeks to foster deeper engagement between CDC senior leaders and public health leadership from the U.S. territories and freely- associated states.

**34) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html)

**Deadline:** May 3, 2021

**Description of Opportunity:** NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

**35) Sponsor(s):**Department of State – Office of the Secretary

**Program Title:** [COVID-19 Private Sector Engagement & Partnership Fund](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328509)

**Deadline:** May 28, 2021

**Description of Opportunity:** The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards.. This APS is being done in partnership the U.S. Agency for International Development and concept papers may be transferred to the Agency based upon a determination of suitability for award and administration. USAID’s policies and procedures will apply to concept papers that are transferred to the Agency. This APS utilizes a two-step process. Applicants must first submit a concise (5-page) concept paper designed to clearly communicate their program idea and objectives. This is not a full proposal. The purpose of the concept paper is to allow applicants to submit program ideas for evaluation prior to requiring the development of a full proposal application. After merit review of eligible concept papers, selected applicants will be invited to expand on their program idea(s) by submitting a full proposal application. Full proposals will go through a second merit review before a final funding decision is made. E/GP has outlined the process through which potential applicants may apply in Appendix 1 to this APS.

**36) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects

**Deadline:** June 11, 2021

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight the critical need to develop prophylactic vaccines able to provide broad and durable protection against coronaviruses (CoVs), especially SARS-CoV-2 and others with pandemic potential. NIAID is particularly interested in highly collaborative, multi-disciplinary Program Projects (P01s) that incorporate understanding of CoV virology and immunology, immunogen design, and innovative vaccine and adjuvant platforms and technologies to discover, design, and develop pan-coronavirus (pan-CoV) vaccine candidates that provide broad protective immunity to multiple CoV strains.

**37) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html)

**Deadline:** Applications will be accepted on a rolling basis July 2, 2020 to July 2, 2021 through 5:00 PM local time of the applicant organization

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces [NOT-AI-20-034](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html) which was rescinded with this issuance of this Notice.

**38) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html)

**Deadline:** July 7, 2021

**Description of Opportunity:** The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAIDs vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAIDs emergency appropriation provided by The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 and The Coronavirus Aid, Relief and Economic Security (CARES) Act.

**39) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_Section_III._Eligibility)

**Deadline:** Applications for this limited competition FOA will be accepted on a rolling basis, beginning July 13, 2020 until July 08, 2021

**Description of Opportunity:** The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.

**40) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html)

**Deadline:** July 9, 2021

**Description of Opportunity:** National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

**41) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-051.html)

**Deadline:** September 7, 2021

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in select scientific areas.

**42) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-065.html)

**Deadline:** September 14, 2021

**Description of Opportunity:** This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in [PAR-18-633](https://grants.nih.gov/grants/guide/pa-files/par-18-633.html) and [NOT-AI-16-084](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-16-084.html), that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:

* SARS-CoV-2 candidate vaccines
* non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
* therapeutic approaches to treat COVID-19

Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative.

**43) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases](https://grants.nih.gov/grants/guide/notice-files/NOT-AR-21-012.html)

**Deadline:** November 19, 2021

**Description of Opportunity:** The purpose of this Notice is to announce to potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) an interest in research on the impact of COVID-19 as related to diseases and conditions within the NIAMS mission.

**44) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html)

**Deadline:** January 25, 2022

**Description of Opportunity:** NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

**45) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html)

**Deadline:** January 25, 2022

**Description of Opportunity:** NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

**46) Sponsor(s):**Department of Defense

**Program Title:** [U.S. Army Contracting Command Medical Countermeasures (MCM) Commercial Solutions Opening (CSO)](https://beta.sam.gov/opp/07c28cf32d6244bc877fbf6dd1e2d2bc/view)

**Deadline:** September 30, 2022

**Description of Opportunity:** This is a Program Announcement for a Medical Countermeasures (MCM) Commercial Solutions Opening (CSO) W911QY-20-S-C001 by the U.S. Army Contracting Command – Aberdeen Proving Ground, Natick Division (ACC-APG-Natick) on behalf of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND) and Biomedical Advanced Research and Development Authority (BARDA). This CSO is in support of Operation Warp Speed in response to the Corona Virus 2019 (COVID-19) pandemic. This CSO Solicitation is a competitive solicitation that is continuously open until September 30, 2022. The government reserves the right to extend this CSO beyond the open until date by amendment if the authority is extended. See attachment ACC-APG-Natick MCM CSO Solicitation W911QY-20-S-C001 for the MCM solicitation. The first AoI is posted with the release of the MCM CSO Solicitation. Future AoI’s will be posted as a Related Notice to this Solicitation.

**47) Sponsor(s):**Department of Health and Human Services

**Program Title:** [BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement](https://beta.sam.gov/opp/f922eb52cec446c5875811752bf2d34c/view) (revised)

**Deadline:** February 3, 2023

**Description of Opportunity:** Please see Special Instructions 012 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 012, BARDA is now accepting abstract submissions for "AOI #1: ENACT (Early Notification to Act, Control and Treat)” and "AOI#2: Infection Severity & Solving Sepsis.” Additionally, “AOI #4.3: Alternative Routes of Administration (AROA) for Vaccines” is now “AOI #6: Beyond the Needle.”

The development of adjunctive diagnostic technologies with near-term impact that are critical to improving the efficiency and effectiveness of our health infrastructure during the COVID-19 outbreak. These technologies may empower the patient through providing a means of self-monitoring or empower the healthcare provider through remote monitoring or evaluation and diagnostic capability throughout the care continuum of the patient (i.e. pre-hospital, inpatient, and post-discharge).

AOI #4.3: Alternative Routes of Administration (AROA) for Vaccines is revised

AOI #4.4: [CLOSED]

AOI#6: Beyond the Needle

The administration of therapeutics, such as vaccines, biologics, or other medications, can be markedly enhanced by utilizing alternative routes of administration that rely less on a needle and syringe approach used in traditional intravenous (IV), intramuscular (IM), or subcutaneous (SC) administrations. These traditional routes via a needle and syringe are often logistically challenging, rely on cold-chain storage that hinders distribution, and almost exclusively require experienced personnel for administration.

The DRIVe Beyond the Needle program seeks to develop technologies that (1) utilize alternative routes of administration for administering therapeutics, such as but not limited to: oral, intranasal, transdermal patches, sublingual, and buccal mechanisms of administration, (2) involve simplified logistics that enable easier deployment and uptake, and (3) able to be administered without a

trained health-care professional.

As a consequence to reduce production costs, the medical supply industry has evolved to “just-in-time” supply chain models that involve sourcing and manufacturing raw materials outside the United States. As a result, the domestic availability of needle and syringes is limited and poses as a bottleneck for therapies requiring their use on a large scale. In recent months, the pandemic has highlighted opportunities to strengthen and bolster the United States medical supply chain. The Beyond the Needle program seeks to develop therapeutics that can be administered in a broad range of care settings including within the home and do not rely on skilled medical personnel for administration. A successful alternative technology for administration would reduce the demand placed on qualified personnel, particularly in communities that are underserved and have reduced access to care.

BARDA is seeking abstracts for the development of technology that features an alternative route of administration for any type of payload, including vaccines, drugs (biologics, small molecules, nucleic acids), as well as adjuvants against CBRN threats, Influenza (seasonal/pandemic), coronaviruses (SARS-CoV-2), and other emerging infectious diseases that is of pandemic concern as outlined on www.medicalcountermeasures.gov.

The ideal attributes for therapeutics or adjuvants delivered via alternative routes of administration would be single dose (although additional dosing is acceptable), room temperature-stable without the need for cold-chain storage, and indicated for all populations. Therapeutics delivered via alternate routes of administration should have similar or superior performance characteristics as traditional routes administered via a needle and syringe (i.e. safety and efficacy).

**48) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection](https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-084.html)

**Deadline:** September 8, 2024

**Description of Opportunity:** The purpose of this notice is to communicate NIDA’s interest in supporting research on **the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.**

**49) Sponsor(s):**Department of Health and Human Services

**Program Title:** [SARS-CoV-2 (COVID-19) Program Activities](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328065)

**Deadline:** Forecast

**Description of Opportunity:**The Office of the Assistant Secretary for Health (OASH) has established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a Broad Agency Announcement (BAA) “to prevent, prepare for, and respond to coronavirus, domestically or internationally, for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19…” (Paycheck Protection Program and Healthcare Enhancement Act (P.L. 116-139)). OASH/LDWG seeks proposals for projects that will further enable the coordination and development of testing and associated products that meet the current and future needs, and the effective transition of technology into broad use without impediments. The primary areas of focus should specifically include (1) Scaling and Networking of Technologies, and (2) Testing Demonstrations & Technical Assistance. Specifically, OASH is interested in submissions that will substantially increase our testing capacity and quality in the near term, and do not fall within the scope of other HHS programs.

When posted, the funding opportunity announcement (FOA) will provide guidance for applicants on the submission of short white papers, which after review, may be followed by full proposal submissions for consideration for funding. Applicants will have the option of forgoing the white paper submission for direct submission of a full proposals. Applications will be accepted and reviewed on a rolling basis to address immediate public needs. Applicants must submit white papers and applications through Grants.gov according to the instructions in the FOA. Applicants must have an active SAM registration at the time of submission and maintain an active registration throughout the review process and during any award that may result.

**50) Sponsor(s):**Department of Health and Human Services – Agency for Health Care Research and Quality

**Program Title:** [Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19](https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-007.html)

**Deadline:** Notice of Intent

**Description of Opportunity:**AHRQ intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare professional response to COVID-19. Grant activity codes to be included or excluded from the funding notice will specified in the announcement.

It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. Competitive revision supplements will be limited in duration (perhaps 12 months). The amount of supplemental funds that may be requested will be limited, and will be specified in the funding notice. AHRQ expects to make at least $2.5M available to fund meritorious revision supplements in FY2020. AHRQ plans to release the supplement announcement in April 2020 with an opening date in mid-May.

Please also see AHRQ’s Notice of Intent to publish a new FOA requesting new competitive applications targeting the evaluation of health system responsiveness to COVID-19.

**51) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html)

**Deadline:** Varies

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

**52) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-020.html)

**Deadline:** Varies

**Description of Opportunity:** NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

**53) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PA-20-163.html)

**Deadline:** Varies

**Description of Opportunity:**The National Institutes of Health (NIH) hereby notifies NIH award recipients that funds may be available for revision applications to support the expansion of existing projects and/or programs within the awarding IC identified in the competitive revision NOSI. Applications for Revisions will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria.

Only applications submitted in response to a NOSI published by an NIH Institute or Center will be allowed to apply to this FOA.

**54) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html)

**Deadline:** Varies

**Description of Opportunity:**The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.

**55) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of NHGRI’s Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"](https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html)

**Deadline:** Varies

**Description of Opportunity:**The purpose of this Notice is to inform applicants that the National Human Genome Research Institute (NHGRI) will participate, effective immediately, in **PA-18-935** "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)".

**56) Sponsor(s):**National Science Foundation (NSF)

**Program Title:** [Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)](https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp)

**Deadline:** No firm deadline announced

**Description of Opportunity:** Through this Dear Colleague Letter, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the [Computational and Data-Enabled Science and Engineering (CDS&E) program](https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504813) or the [Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program](https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505505).RAPID is a type of proposal used when there is a severe urgency with regard to availability of, or access to, data, facilities or specialized equipment, including quick-response research on natural or anthropogenic disasters and similar unanticipated events. PI(s) must contact the NSF Program Officer(s) whose expertise is most germane to the proposal topic before submitting a RAPID proposal. This will facilitate determining whether the proposed work is appropriate for RAPID funding.

**57) Sponsor(s):**National Science Foundation (NSF)

**Program Title:** [Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)](https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp)

**Deadline:** No firm deadline announced

**Description of Opportunity:** In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

**58) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement -  Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html)

**Deadline:** Varies

**Description of Opportunity:** The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

**59) Sponsor(s):**National Institute of Health Research (NIHR)

**Program Title:** [Travel and Subsistence Funding to Support LMIC Engagement During the COVID-19 Outbreak](https://www.nihr.ac.uk/documents/travel-and-subsistence-funding-to-support-lmic-engagement-during-the-covid-19-outbreak-guidance/24356)

**Deadline:** Open until further notice

**Description of Opportunity:** This scheme provides travel and subsistence funding to support delivery of technical expertise in the global response to Covid-19. This service is not delivered to, or on behalf of, the Department of Health and Social Care (DHSC)/the National Institute for Health Research (NIHR) and does not constitute a contractual or service agreement, employer/employee or agent/principal relationship between any institution, body or person and the DHSC/NIHR.

**60) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing](https://www.poctrn.org/radx)

**Deadline:** Accepting proposals for support on a rolling basis until further notice

**Description of Opportunity:** As part of this initiative, NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will be put through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. Finalists will be matched with technical, business and manufacturing experts to increase the odds of success. If certain selected technologies are already relatively far along in development, they can be put on a separate track and be immediately advanced to the appropriate step in the commercialization process. The goal is to make millions of accurate and easy-to-use tests per week available to all Americans by the end of summer 2020, and even more in time for the flu season.

**61) Sponsor(s):**California Institute for Regenerative Medicine (CIRM)

**Program Title:** [Special Call for COVID-19 Projects](https://www.cirm.ca.gov/sites/default/files/files/funding_page/COVID19-SA_0.pdf)

**Deadline:** Rolling

**Description of Opportunity:** The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. Given the growing surge of COVID-19 cases in California and throughout the world, CIRM is issuing this special announcement to support promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments to COVID-19 patients in need. CIRM is utilizing its established partnering opportunities across Discovery (DISC2), Translational (TRAN1), and Clinical (CLIN1, CLIN2) stages to provide support for COVID-19 related projects.

**62) Sponsor(s):**Alianza UCMX

**Program Title:** [Alianza UCMX Supplemental COVID-19 Funding Opportunity](https://ucmexus.ucr.edu/funding/alianza-pdf/Supplemental_Funding_Opportunity_final.pdf)

**Deadline:** Rolling

**Description of Opportunity:** Alianza UCMX (alianzaucmx.ucr.edu) is proud to release the UC MEXUS (ucmexus.ucr.edu) supplemental funding opportunity for UC faculty undertaking research on COVID-19 who want to engage with Mexico. To be eligible, UC faculty must be a recipient of a coronavirus-related project award and be interested in expanding their academic engagement with faculty; graduate, professional, and undergraduate students; or researchers from a Mexican higher education institution.

**63) Sponsor(s):**Department of Commerce

**Program Title:** [FY 2020 EDA Public Works and Economic Adjustment Assistance Programs including CARES Act Funding](https://www.grants.gov/web/grants/view-opportunity.html?oppId=321695)

**Deadline:** Rolling

**Description of Opportunity:** Under this NOFO, EDA solicits applications from applicants in rural and urban areas to provide investments that support construction, non-construction, technical assistance, and revolving loan fund projects under EDA’s Public Works and EAA programs. Grants and cooperative agreements made under these programs are designed to leverage existing regional assets and support the implementation of economic development strategies that advance new ideas and creative approaches to advance economic prosperity in distressed communities. EDA provides strategic investments on a competitive- merit-basis to support economic development, foster job creation, and attract private investment in economically distressed areas of the United States. If you are interested in applying for a project of national impact/scope under the CARES Act; please inquire at RNTA@eda.gov.

**64) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)](https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html)

**Deadline:** Rolling

**Description of Opportunity:** The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

**65) Sponsor(s):**The Gates Foundation, Wellcome Trust, and the Mastercard Impact Fund

**Program Title:** [The COVID-19 Therapeutics Accelerator](https://wellcome.ac.uk/news/wellcome-pledges-50-million-new-initiative-speed-development-covid-19-treatments)

**Deadline:** Varies

**Description of Opportunity:** Currently there are no approved treatments for COVID-19. This new initiative aims to fill that gap by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The partners are committed to equal access, ensuring treatments are accessible and affordable in low-resource settings.

**66) Sponsor(s):**Mozilla

**Program Title:** [COVID-19 Solutions Fund](https://blog.mozilla.org/blog/2020/03/31/moss-launches-covid-19-solutions-fund/)

**Deadline:** Continuous

**Description of Opportunity:** As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).

**67) Sponsor(s):**George Mason University; Mercatus Center; Emergent Ventures

**Program Title:** [Fast Funding for COVID-19 Science](https://fastgrants.org/)

**Deadline:** Continuous

**Description of Opportunity:** Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this.

If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant.

**68) Sponsor(s):**Adira Foundation

**Program Title:** [Fast-Track Grant Response: COVID-19](https://adirafoundation.org/programs/adiras-fast-track-grant-response-covid-19/)

**Deadline:** Continuous

**Description of Opportunity:** Adira Foundation is redirecting some funding to meet immediate and pressing needs. Adira is fast tracking the grant application process so that organizations seeking financial support can act quickly to provide emergency response, direct-service programs to the Alzheimer's disease, ALS, Huntington's disease, multiple sclerosis, or Parkinson's disease communities.

**69) Sponsor(s):**Open Road Alliance

**Program Title:** [Direct COVID-19 Response – Charitable Grant](https://openroadalliance.org/covid-19/)

**Deadline:** Continuous

**Description of Opportunity:** The effect of the COVID-19 pandemic on the impact sector has reached natural disaster proportions in its scope and scale, which means that the global need for our 'emergency' capital vastly outstrips our available resources. Charitable Grants will only be offered to organizations responding directly to COVID-19. This grant is for organizations engaging in direct COVID-19 response. We will prioritize organizations and activities that have a clear and direct role in `flattening the curve' and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Slowing and stopping the spread of COVID-19 is directly linked to reducing and limiting the economic and social hardship our communities are experiencing.

**70) Sponsor(s):** United States Agency for International Development (USAID)

**Program Title:** [COVID-10 Funding Requests and Unsolicited Proposals](https://www.usaid.gov/coronavirus/funding-requests-unsolicited-proposals)

**Deadline:** No firm deadline announced

**Description of Opportunity:** USAID is responding to the COVID-19 pandemic with decisive action at home and abroad. The priorities in the COVID-19 response are to protect the safety and health security of the global workforce, ensure that USAID can continue its life-saving mission across the world, and support partner countries in their response to COVID-19. Partners may submit unsolicited proposals to COVID19\_Concepts@usaid.gov.

**71) Sponsor(s):** State of California

**Program Title:** [State of California COVID-19 Technology Solutions](https://tech.covid19.ca.gov/)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The State of California is interested in learning more about potential case management/CRM software solutions for COVID-19 contact tracing. Solutions should be scalable, proven, easy to learn and use, and HIPAA-compliant, with strong role management, the ability to easily configure COVID-19-specific scripts and alerts, the ability to easily support 3rd party integrations, and features (such as automated two-way messaging) that can help maximize the productivity of contact tracing staff.

The State is also interested in learning about potential solutions for contact tracing call center operations and management, including the ability to operate a HIPAA-compliant virtual call center with home-based agents, ramp up new staff quickly, and provide them with the support necessary to be successful.

**72) Sponsor(s):** Congressional Hispanic Caucus Institute (CHCI)

**Program Title:** [COVID-19 Response Fund as Economic Relief to Latino Community](https://chci.org/covid-19-response-fund/)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The Congressional Hispanic Caucus Institute (CHCI) announced the launch of a COVID-19 Response Fund to provide economic relief to Hispanics who are among the hardest hit and most vulnerable communities impacted by the deadly Coronavirus outbreak. They are currently developing a list of qualified 501(c)(3) nonprofit organizations who have good reputations (for example, on GuideStar), and who provide direct services and other COVID-19 related support and resources to those in need. CHCI will distribute dollars received through the COVID-19 Response Fund to those organizations. The list of organizations will be posted on their website, available to the public.

**73) Sponsor(s):** National Institutes of Health (NIH)

**Program Title:** [Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis](https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-054.html)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

NCI anticipates that in infrequent cases, NCI-funded investigators will have novel insights and research proposals of immediate relevance to SARS-CoV-2 and COVID-19. In those cases, but only for the duration of the present crisis, NCI would consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources under the following conditions:

* Any proposed COVID-19 projects would have to be novel, innovative, compelling, and scientifically meritorious. Projects should have cancer relevance and the potential for high impact.
* Proposed projects should not duplicate other efforts or be simple extensions or modifications of ongoing research.
* Proposed projects must be able to start immediately and be time limited, not to exceed 1 year.
* If the proposed research requires access to laboratories and facilities currently not available, the sponsoring institution must provide explicit concurrence that those facilities would be made available for the project.
* The investigator must have the resource capacity within the existing NCI grant to pursue the project.

**74) Sponsor(s):** Novaritis Foundation

**Program Title:** [Novaritis US COVID-19 Initiatives](https://www.novartis.us/news/novartis-us-covid-19-initiatives)

**Deadline:** No firm deadline announced

**Description of Opportunity:** In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic. Programs must support one or more of the three stated objectives:

* Strengthening local and national healthcare infrastructure to meet increased demand and protect frontline health workers
* Establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information
* Creating or enhancing new community health programs specific to the pandemic response

**75) Sponsor(s):** Draper Richards Kaplan Foundation

**Program Title:** [DRK COVID-19 Urgent Response Initiative (CURI)](https://drive.google.com/file/d/1Dcj2zuFKE72caEBYz5ADOLDWeci802cD/view)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The Draper Richards Kaplan Foundation invites applications for funding under its COVID-19 urgent response initiative. This supports innovative solutions that address time-critical social problems caused by the COVID-19 pandemic. Solutions should be fully scalable, lead to lasting change and be deployable within 30 days.